Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$26.5M, compared with -$21.89M a year earlier. Trailing-twelve-month operating income was -$91.32M.

Context

  • Operating income amounted to 3099.9% of revenue in FY2025, up 2987.1 pp from a year earlier.
  • Operating income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 5 analysts of -$52.89M (+39.0%) for the fiscal year ending Dec 2026, a step up from the -97.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.5M-20.8% QoQ
Last fiscal yearDec 2025
-$86.71M-97.5% YoY
LTMMar 2026
-$91.32M-74.1% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.1%-18.1%+3.0 pp
1 year-97.5%+39.0%+136.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(86.71M) USD
Year-over-year change
-97.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -74.1% is the 8th highest of 9, against a peer median of -34.3%.
  • Operating income amounts to 5144.5% of revenue for RNAC, versus a peer median of 193.6%.
RNAC Competitors
Operating Income for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-$5.63M USD+53.2%—11.0%
MDWDMediWound Ltd.LTM Mar 2026-$28.03M USD-34.3%—193.6%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$33.4M USD———
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$45.1M USD-64.4%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$54.96M USD+20.1%—168.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$64.12M USD+18.5%——
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026-$74.72M USD-140.4%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$79.16M USD-57.0%—134164.4%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$91.32M USD-74.1%—5144.5%
IVAInventiva S.A.FY2025-€130.95M EUR-34.2%—2921.0%
Peer median (excluding RNAC) —-34.3%—193.6%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.